ELDN Archived Articles
Eledon Pharmaceuticals (NASDAQ:ELDN): A Biotech Tackling Transplant Rejection and Autoimmune Diseases
Published on March 12, 2025
Eledon Pharmaceuticals (ELDN): Advancing Innovative Therapies to Transform Transplant and Autoimmune Care
Published on November 17, 2024
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN): A Promising Biotech Poised for Transformative Advancements
Published on September 24, 2024